| Previous Close | 13.55 |
| Open | 13.58 |
| Bid | 13.00 x 400 |
| Ask | 13.02 x 100 |
| Day's Range | 12.99 - 13.64 |
| 52 Week Range | 8.18 - 15.20 |
| Volume | 937,537 |
| Avg. Volume | 1,265,782 |
| Market Cap | 1.82B |
| Beta | 2.56 |
| PE Ratio (TTM) | -14.38 |
| EPS (TTM) | -0.91 |
| Earnings Date | Aug 7, 2017 - Aug 11, 2017 |
| Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 16.77 |
- PR Newswire•yesterday
Halozyme Phase 2 Data In Advanced Pancreas Cancer Presented At European Society For Medical Oncology Symposium
--Findings in Two Oral Presentations and Three Poster Presentations Continue to Support Ongoing HALO-301 Phase 3 Study-- BARCELONA, Spain , June 28, 2017 /PRNewswire/ -- Results from Halozyme Therapeutics ...
- Capital Cube•3 days ago
ETFs with exposure to Halozyme Therapeutics, Inc. : June 26, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Halozyme Therapeutics, Inc. Here are 5 ETFs with the largest exposure to HALO-US. Comparing the performance and risk of Halozyme Therapeutics, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
- Accesswire•3 days ago
Halozyme FDA Action Date, Q1 Review, Analysts Outlook and Price Targets
NEW YORK, NY / ACCESSWIRE / June 26, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive ...